Blockchain Registration Transaction Record

Pelage Pharma Raises $120M for Stem Cell Hair Therapy Breakthrough

Pelage Pharmaceuticals secures $120M Series B funding to advance PP405, a regenerative hair growth therapy that activates dormant follicle stem cells. Clinical-stage biotech innovation.

This development represents a potential paradigm shift in hair restoration treatment, moving beyond cosmetic solutions to address the biological root causes of hair loss. For the millions affected by androgenetic alopecia and other forms of hair loss, Pelage's approach could offer a scientifically validated, non-invasive treatment that activates the body's natural regenerative capabilities. Unlike hair transplants or topical minoxidil, which primarily manage symptoms, this stem cell activation therapy aims to restore natural hair growth by targeting dormant follicles. The substantial investment from top-tier venture firms indicates strong confidence in both the science and market potential, suggesting we may be approaching a new era in dermatological treatments where regenerative medicine delivers tangible solutions for conditions that significantly impact self-esteem and quality of life.